Dataset Information

Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using ²¹¹At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response.

ABSTRACT: Small cell lung cancer (SCLC) is a neuroendocrine tumor with a high degree of malignancy. Due to limited treatment options, patients with SCLC have a poor prognosis. We have found, however, that intravenously administered octreotide (Oct) armed with astatine-211 ([²¹¹At]SAB-Oct) is effective against a somatostatin receptor 2 (SSTR2)-positive SCLC tumor in SCLC tumor-bearing BALB/c nude mice. In biodistribution analysis, [²¹¹At]SAB-Oct achieved the highest concentration in the SCLC tumors up to 3 h after injection as time proceeded. A single intravenous injection of [²¹¹At]SAB-Oct (370 kBq) was sufficient to suppress SSTR2-positive SCLC tumor growth in treated mice by inducing DNA double-strand breaks. Additionally, a multitreatment course (370 kBq followed

SUBMITTER: Qin S

PROVIDER: S-EPMC10630944 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using ²¹¹At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using ²¹¹At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response.